There are currently 207 clinical trials in Worcester, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Massachusetts Medical School, UMass Memorial Medical Center, University of Massachusetts Memorial Medical Center and UMass Memorial Medical Center - University Campus. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/28/2025
Locations: UMass Memorial Medical Center, Worcester, Massachusetts
Conditions: Primary Generalized Tonic-Clonic Seizures
Register for Updates
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788
Recruiting
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS. All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: University of Massachusetts Chan Medical School-Division of Hematology/Oncology ( Site 0144), Worcester, Massachusetts
Conditions: Non-small Cell Lung Cancer (NSCLC)
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: UMass Memorial Medical Center, Worcester, Massachusetts
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With Autoimmune Disease (Ntrust-1)
NCT06557265
Recruiting
This is an open-label, multi-center, non-randomized Phase 1 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with active lupus nephritis (LN).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/21/2025
Locations: University of Massachusetts, Worcester, Massachusetts
Conditions: Lupus Nephritis, Glomerulonephritis
Register for Updates
Enhanced Coordinated Specialty Care for Early Psychosis
NCT06071858
Recruiting
The goal of this clinical trial is to compare engagement in treatment in coordinated specialty care (CSC) to five extra care elements (CSC 2.0) in first-episode psychosis. The main question it aims to answer is: • Does the addition of certain elements of care increase the number of visits in treatment for first-episode psychosis? Participants will either: * Receive care as usual (CSC) or * Receive care as usual (CSC) plus five additional care elements (CSC 2.0): 1. Individual peer support... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/20/2025
Locations: UMass Memorial Community Healthlink STEP Clinic, Worcester, Massachusetts
Conditions: Psychosis, Schizophrenia, Schizoaffective Disorder, Psychosis Nos/Other, Bipolar Disorder
Register for Updates
Efficacy, Effectiveness, and Implementation of Jaspr Health in Emergency Department- Part a
NCT06223867
Recruiting
This Study will comprehensively evaluate a multi-component suicide prevention technology (Jaspr Health) that facilitates delivery of suicided-related evidence-based practices (EBPs) while replacing wasted waiting time with productive time in the Emergency Departments (EDs). The EBPs satisfy several key performance elements for systems adopting Zero Suicide. A Complementary Randomized Controlled Trial and Real-World Study for Efficacy, Effectiveness, and Implementation Study Design (CREID) will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: UMass Memorial Health, Worcester, Massachusetts
Conditions: Suicidal Ideation, Suicide Attempt, Self Harm
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: UMass Memorial Medical Center - University Campus, Worcester, Massachusetts
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
REBYOTA™ Prospective Registry
NCT05835219
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Worcester, Massachusetts
Conditions: Recurrence of Clostridium Difficile Infection
Register for Updates
RESPONDER-HF Trial
NCT05425459
Recruiting
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/11/2025
Locations: UMass Memorial Hospital University Campus, Worcester, Massachusetts
Conditions: Heart Failure, Heart Failure, Diastolic
Register for Updates
Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder
NCT06384157
Recruiting
The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently initiated or completed short-term medically supervised withdrawal with transmucosal (TM) buprenorphine, and are interested in transitioning to a non opioid treatment.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/04/2025
Locations: Vitalix Clinical, Worcester, Massachusetts
Conditions: Opioid Use Disorder
Register for Updates
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05076175
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
02/04/2025
Locations: University of Massachusetts Chan Medical School, Worcester, Massachusetts
Conditions: Colitis, Ulcerative
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of Massachusetts Worcester, Worcester, Massachusetts
Conditions: Triple Negative Breast Cancer
Register for Updates